Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria
Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods. The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IRBIS LLC
2019-07-01
|
| Series: | Фармакоэкономика |
| Subjects: | |
| Online Access: | https://www.pharmacoeconomics.ru/jour/article/view/289 |
| _version_ | 1797878912736296960 |
|---|---|
| author | S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova |
| author_facet | S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova |
| author_sort | S. V. Nedogoda |
| collection | DOAJ |
| description | Aim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods. The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost-effectiveness and budget impact analyses were performed using the Microsoft Excel software.Results. The treatment efficacy analysis showed that patients treated with the fixed-dose combination ceftazidime + avibactam had fewer days spent in the ICU and higher clinical cure rates than patients receiving the reference drug combinations (8 vs 18 days and 75% vs 34.8%, respectively, p=0.031). The cost of treatment with ceftazidime + avibactam amounted to 228.3 thousand rubles, which was lower than the cost of using the alternative treatment regimens by 34.5-229.5 thousand rubles or 13.12-50.14%. According to the cost-effectiveness analysis, the use of ceftazidime + avibactam is pharmacoeconomically effective as it reduces the cost of patient clinical cure case by 61-72% (depending on the treatment regimen used); in addition, the ceftazidime + avibactam allows for managing the hospitalized patient at a cost lower by 76270 thousand rubles or 16-40% than the compared treatment. The median economic benefit from using the fixed dose combination ceftazidime + avibactam is 154 thousand rubles (28% savings compared with the current practice). The budget impact analysis showed that the reduction in the health budget burden would reach 29% or 34.3 million rubles in year. The sensitivity analysis confirmed the above results.Conclusion. Based on the obtained results, we conclude that the ceftazidime + avibactam combination in patients with sepsis caused by carbapenem-resistant bacteria is economically preferable as compared with the current antibiotic therapy regimens. |
| first_indexed | 2024-04-10T02:40:42Z |
| format | Article |
| id | doaj.art-e77b644578b8405bbc3c844dd2de146e |
| institution | Directory Open Access Journal |
| issn | 2070-4909 2070-4933 |
| language | Russian |
| last_indexed | 2024-04-10T02:40:42Z |
| publishDate | 2019-07-01 |
| publisher | IRBIS LLC |
| record_format | Article |
| series | Фармакоэкономика |
| spelling | doaj.art-e77b644578b8405bbc3c844dd2de146e2023-03-13T07:48:16ZrusIRBIS LLCФармакоэкономика2070-49092070-49332019-07-01122728410.17749/2070-4909.2019.12.2.72-84259Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteriaS. V. Nedogoda0A. S. Salasyuk1I. N. Barykina2V. O. Smirnova3Volgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityVolgograd State Medical UniversityAim: to assess the economic outcomes of using ceftazidime + avibactam (compared with the recommended treatments) in adult patients with sepsis caused by carbapenem-resistant enterobacteria.Methods. The economic assessment was made using the cost-effectiveness analysis and budget impact analysis. The cost-effectiveness and budget impact analyses were performed using the Microsoft Excel software.Results. The treatment efficacy analysis showed that patients treated with the fixed-dose combination ceftazidime + avibactam had fewer days spent in the ICU and higher clinical cure rates than patients receiving the reference drug combinations (8 vs 18 days and 75% vs 34.8%, respectively, p=0.031). The cost of treatment with ceftazidime + avibactam amounted to 228.3 thousand rubles, which was lower than the cost of using the alternative treatment regimens by 34.5-229.5 thousand rubles or 13.12-50.14%. According to the cost-effectiveness analysis, the use of ceftazidime + avibactam is pharmacoeconomically effective as it reduces the cost of patient clinical cure case by 61-72% (depending on the treatment regimen used); in addition, the ceftazidime + avibactam allows for managing the hospitalized patient at a cost lower by 76270 thousand rubles or 16-40% than the compared treatment. The median economic benefit from using the fixed dose combination ceftazidime + avibactam is 154 thousand rubles (28% savings compared with the current practice). The budget impact analysis showed that the reduction in the health budget burden would reach 29% or 34.3 million rubles in year. The sensitivity analysis confirmed the above results.Conclusion. Based on the obtained results, we conclude that the ceftazidime + avibactam combination in patients with sepsis caused by carbapenem-resistant bacteria is economically preferable as compared with the current antibiotic therapy regimens.https://www.pharmacoeconomics.ru/jour/article/view/289sepsiscarbapenem-resistant enterobacteriabacteria with multiple resistanceceftazidime + avibactambudget impact analysiscost-effectiveness analysis |
| spellingShingle | S. V. Nedogoda A. S. Salasyuk I. N. Barykina V. O. Smirnova Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria Фармакоэкономика sepsis carbapenem-resistant enterobacteria bacteria with multiple resistance ceftazidime + avibactam budget impact analysis cost-effectiveness analysis |
| title | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria |
| title_full | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria |
| title_fullStr | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria |
| title_full_unstemmed | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria |
| title_short | Pharmacoeconomic analysis of ceftazidime+avibactam (Zavicefta®) in the treatment of sepsis caused by carbapenem-resistant enterobacteria |
| title_sort | pharmacoeconomic analysis of ceftazidime avibactam zavicefta r in the treatment of sepsis caused by carbapenem resistant enterobacteria |
| topic | sepsis carbapenem-resistant enterobacteria bacteria with multiple resistance ceftazidime + avibactam budget impact analysis cost-effectiveness analysis |
| url | https://www.pharmacoeconomics.ru/jour/article/view/289 |
| work_keys_str_mv | AT svnedogoda pharmacoeconomicanalysisofceftazidimeavibactamzaviceftainthetreatmentofsepsiscausedbycarbapenemresistantenterobacteria AT assalasyuk pharmacoeconomicanalysisofceftazidimeavibactamzaviceftainthetreatmentofsepsiscausedbycarbapenemresistantenterobacteria AT inbarykina pharmacoeconomicanalysisofceftazidimeavibactamzaviceftainthetreatmentofsepsiscausedbycarbapenemresistantenterobacteria AT vosmirnova pharmacoeconomicanalysisofceftazidimeavibactamzaviceftainthetreatmentofsepsiscausedbycarbapenemresistantenterobacteria |